You are here: Industry Insights > InnoCare

News List

Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology PharmaSources
February 07, 2023
American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI PharmaSources
January 06, 2023
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China PharmaSources.com
December 20, 2022
InnoCare Pharma announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial.
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales PharmaSources.com
November 16, 2022
InnoCare Pharma announced 2022 third quarter results and latest corporate development.
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting PharmaSources.com
June 07, 2022
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China PharmaSources.com
March 30, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China PharmaSources.com
March 28, 2022
InnoCare Pharmaannounced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA...
InnoCare Releases 2021 Annual Results and Business Highlights InnoCare
March 23, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing...

Previous page 1 2 3 4 5 6 Next page